NO943653L - Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon - Google Patents

Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Info

Publication number
NO943653L
NO943653L NO943653A NO943653A NO943653L NO 943653 L NO943653 L NO 943653L NO 943653 A NO943653 A NO 943653A NO 943653 A NO943653 A NO 943653A NO 943653 L NO943653 L NO 943653L
Authority
NO
Norway
Prior art keywords
prevention
treatment
monoclonal antibodies
hiv
neutralizing monoclonal
Prior art date
Application number
NO943653A
Other languages
English (en)
Other versions
NO943653D0 (no
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Syd Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Medimmune Inc filed Critical Merck & Co Inc
Publication of NO943653D0 publication Critical patent/NO943653D0/no
Publication of NO943653L publication Critical patent/NO943653L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Rekombinante, humane HTV-naytraliserende monoklonale antistoffer for forebyggelse og behandling av HTV-infeksjon Rekombinante, humane immun- globulinmolekyler som er nøytraliser- ende for HIV-1, fremgangsmåter for fremstilling av immunglobulinene og fremgangsmåter for forebyggelse av HIV- 1-infeksjon ved anvendelse av immunglo- bulinene. DNA-konstruksjoner innehold- ende de komplementaritetsbestemmende områder (CDR) og rammeverk (FR) for det native, humane antistoff, kombineres med andre konstante områder og uttryk- kes i rekombinante vertsceller. Disse rekombinante antistoffer er anvendelige for behandling og forebyggelse av HIV- 1-infeksjon in vlvo.
NO943653A 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon NO943653L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO943653D0 NO943653D0 (no) 1994-09-30
NO943653L true NO943653L (no) 1994-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943653A NO943653L (no) 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Country Status (19)

Country Link
EP (1) EP0577243A3 (no)
JP (1) JPH06217791A (no)
KR (1) KR950700761A (no)
CN (1) CN1081716A (no)
AU (2) AU3928593A (no)
BG (1) BG99074A (no)
CA (1) CA2093099A1 (no)
CZ (1) CZ239694A3 (no)
FI (1) FI944561A7 (no)
HU (1) HUT70461A (no)
IL (1) IL105145A0 (no)
MX (1) MX9301858A (no)
NO (1) NO943653L (no)
NZ (1) NZ251582A (no)
RU (1) RU94045907A (no)
SK (1) SK116294A3 (no)
WO (1) WO1993019785A1 (no)
YU (1) YU22693A (no)
ZA (1) ZA932308B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263778T1 (de) * 1998-10-30 2004-04-15 Novozymes As Niedrigallergene proteinvarianten
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
WO2015117008A2 (en) * 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分
CN118684742B (zh) * 2024-03-06 2026-04-07 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339857C (en) * 1987-05-29 1998-05-05 Cecily Rou-Yun Sun Monoclonal antibodies to gp120 which neutraleze hiv-1
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
IL94624A0 (en) * 1989-06-05 1991-04-15 Repligen Corp Human monoclonal antibodies to hiv-1 mn qq120
AU8228791A (en) * 1990-06-15 1992-01-07 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
AU668134B2 (en) * 1992-01-29 1996-04-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The AAMP-1, a protein with local homologies to HIV-1 ENV and NEF proteins

Also Published As

Publication number Publication date
FI944561A0 (fi) 1994-09-30
AU3928593A (en) 1993-11-08
YU22693A (sh) 1997-01-08
CN1081716A (zh) 1994-02-09
EP0577243A3 (en) 1994-11-02
NO943653D0 (no) 1994-09-30
CZ239694A3 (en) 1995-07-12
CA2093099A1 (en) 1993-10-02
KR950700761A (ko) 1995-02-20
JPH06217791A (ja) 1994-08-09
FI944561L (fi) 1994-09-30
FI944561A7 (fi) 1994-09-30
HU9402824D0 (en) 1994-11-28
HUT70461A (en) 1995-10-30
RU94045907A (ru) 1996-11-10
MX9301858A (es) 1994-03-31
EP0577243A2 (en) 1994-01-05
AU3563093A (en) 1993-10-07
IL105145A0 (en) 1993-07-08
BG99074A (bg) 1995-11-30
SK116294A3 (en) 1996-11-06
WO1993019785A1 (en) 1993-10-14
NZ251582A (en) 1997-07-27
ZA932308B (en) 1994-09-30
AU658987B2 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
ATE373712T1 (de) Natürlicher menschlicher antikörper
DK0666868T3 (da) Anvendelse af anti-VEGF-antistoffer til behandling af cancer
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
CA2310888A1 (en) Monoclonal human natural antibodies
ES2145004T3 (es) Derivados de anticuerpos.
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
DK0546076T3 (da) Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock
DK0493446T3 (da) Behandling af autoimmunsygdom.
DE69333484D1 (de) Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
NO984851L (no) DHEA kombinasjonsterapi
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application